Sapanisertib phosphate

Sapanisertib phosphate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2017 Jun 8:8:15617. [Abstract]

Customer Validation
Immunoblot analysis of KRAS protein levels in parental (P) and resistant derivatives (R1 and R2) following 4 h treatment with the corresponding inhibitor MLN0128 (Sapanisertib).

Sapanisertib phosphate purchased from MedChemExpress. Usage Cited in: Oncogene. 2015 Mar 26;34(13):1729-35. [Abstract]

Customer Validation
INK-128 ablates phosphorylation of the mTORC1 substrates, 4E-BP1 and S6K.

Sapanisertib phosphate purchased from MedChemExpress. Usage Cited in: J Virol. 2014 Oct;88(20):11872-85. [Abstract]

Customer Validation
Representative Western blot from two independent experiments of p-Akt, p-mTOR, mTOR, p-4EBP1, 4EBP1, eIF4E, c-myc, and MTA1 genes in CNE-1-LMP2A cells treated with Rapamycin (50 nM) or INK-128 (200 nM) for 24 h. The quantification of the Western blot signals are analyzed.

Sapanisertib phosphate purchased from MedChemExpress. Usage Cited in: J Virol. 2014 Oct;88(20):11872-85. [Abstract]

Customer Validation
Confocal analysis of MTA1 (red) and β-catenin (green) expression in CNE-1-LMP2A cells treated with Rapamycin (50 nM) or INK-128 (200 nM) for 24 h. The scale bar represents 10 μm. Immunofluorescence analysis of MTA1 and β-catenin expression reveals that MTA1 is decreased and β-catenin is maintained in the cytoplasm when the cells are treated with INK-128.